Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
37 results
D1.281 - Development of a Peanut-Specific Human Mast Cell Assay for Screening Probiotics and other Nutritional Components with Anti-Allergic Potential
D1.284 - Eosinophilic Esophagitis Before and After Milk Oral Immunotherapy in Children with Food Allergy: A Case Series Including the Eosinophil-to-Lymphocyte Ratio
D1.278 - Dragon fruit Allergy: A Case of Cross-Reactivity and Dietary Risks
D1.279 - Oral Immune Tolerance Induction Therapy with IFN-gamma in children with rice allergy
D1.280 - Microbiome Signatures Associated with Food Allergy Resolution in Children
D1.283 - Endolysosomal degradation of major peanut allergens revealed distinct degradation kinetics and T cell epitope regions
D1.285 - Novel food supplement containing a combination of postbiotics and plant-derived compounds regulates epithelial barrier integrity and immune response in human enterocytes
D1.286 - Allergenic Protein Profiling in a Patient with Long-standing Nut-Induced Anaphylaxis
D1.287 - Polysensitization to Seed Storage Proteins, LTPs and Profilin in a Patient With Anaphylaxis After Consumption of Pesto Sauce
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.457 - Hypersensitivity reactions for Enzyme Replacement Therapy in a Patient with Hunter syndrome
D2.460 - Does Aspirin change outcomes of dupilumab therapy?
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download